- Home
- INM vs EYEN Comparison
INM vs EYEN Comparison
Compare INM & EYEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- EYEN
- Stock Information
- Founded
- INM 1981
- EYEN 2014
- Country
- INM Canada
- EYEN United States
- Employees
- INM N/A
- EYEN N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- EYEN Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- EYEN Health Care
- Exchange
- INM Nasdaq
- EYEN Nasdaq
- Market Cap
- INM 3.2M
- EYEN 2.9M
- IPO Year
- INM N/A
- EYEN 2018
- Fundamental
- Price
- INM $3.05
- EYEN $10.36
- Analyst Decision
- INM
- EYEN Hold
- Analyst Count
- INM 0
- EYEN 4
- Target Price
- INM N/A
- EYEN $2.00
- AVG Volume (30 Days)
- INM 9.5M
- EYEN 10.0M
- Earning Date
- INM 05-12-2025
- EYEN 08-11-2025
- Dividend Yield
- INM N/A
- EYEN N/A
- EPS Growth
- INM N/A
- EYEN N/A
- EPS
- INM N/A
- EYEN N/A
- Revenue
- INM $4,920,990.00
- EYEN $67,063.00
- Revenue This Year
- INM N/A
- EYEN $7,680.45
- Revenue Next Year
- INM N/A
- EYEN $315.38
- P/E Ratio
- INM N/A
- EYEN N/A
- Revenue Growth
- INM N/A
- EYEN 663.82
- 52 Week Low
- INM $1.72
- EYEN $0.85
- 52 Week High
- INM $15.70
- EYEN $124.80
- Technical
- Relative Strength Index (RSI)
- INM 51.86
- EYEN 69.13
- Support Level
- INM $3.32
- EYEN $7.50
- Resistance Level
- INM $5.50
- EYEN $14.33
- Average True Range (ATR)
- INM 0.37
- EYEN 2.50
- MACD
- INM 0.06
- EYEN 0.61
- Stochastic Oscillator
- INM 24.69
- EYEN 69.93
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.